Key Highlights

  • On the market data, Davion Healthcare (NASDAQ:DAVI) reached USD 1.58 on Friday, November 6, 2026, up 20.61%, which implies a prior session level near USD 1.31 (calculated).
  • The shares traded at USD 4.04 on October 26, 2026, a 32.67% drop from USD 6.00, leaving the current quote about 61% beneath that level (calculated).
  • Healthcare Stat Homecare is the target of a USD 13.5 million purchase announced on October 29, 2026, funded with USD 8 million cash and USD 5.5 million of stock.
  • The stock portion is valued at USD 13 per share, which works out to roughly 423,000 shares (calculated), far above the current USD 1.58 quote.

Rebound Follows a Sharp Post-Debut Decline

Davion Healthcare (NASDAQ:DAVI) rose 20.61% to USD 1.58 on Friday, November 6, 2026. The search found no company announcement dated November 5 or 6 that accounts for the gain. Its ordinary shares were slated to debut on October 22, 2026 through a Nasdaq Global Market listing, and by October 26 they were quoted at USD 4.04 against a prior reference of USD 6.00. Davion develops non-invasive monitoring technology, with BreastCheck as the lead offering, an at-home breast health screening product carrying FDA registration that detects abnormalities by tracking temperature shifts. Calculated, the Market Price sits about 61% under the October 26 quote.

USD 13.5 Million Home Care Acquisition Details

The October 29, 2026 release described an agreement dated October 27 to purchase Healthcare Stat Homecare, a Philadelphia home healthcare provider. The total is USD 13.5 million, split into USD 8 million in cash plus USD 5.5 million in shares priced at USD 13 each, and completion is anticipated on or before December 31, 2026. On an unaudited basis, the seller's 2025 gross receipts were roughly USD 11.6 million, with ordinary Business income near USD 1.9 million. Management characterized the transaction as the first in a planned series of acquisitions of profitable healthcare operations over the coming year. Glenn Williams was named chief executive and Jeremy North chief operating officer. Services at the target span skilled nursing, home health aides and rehabilitation, covering wound, dementia and diabetes care plus telehealth, and Davion said it may also examine using its monitoring technology in home care.

Valuation Gap and Thin-Trading Risk

The Market Value was USD 101 million on 25 million shares when the stock sat at USD 4.04; at USD 1.58 the same share count implies about USD 39.5 million (calculated). A USD 8 million cash outlay is therefore a big slice of today's value, and the USD 13 deal price is far above the market. Being newly listed, the stock can have its price pushed by a few trades, spreads can run wide, and quoted moves may reverse. Davion's own Revenue figures were not located. Funding for the USD 8 million payment was not confirmed, since no cash balance or financing details were found.

Where Things Stand

What sits behind the bounce is, so far, unexplained by any company statement, and the Healthcare Stat Homecare purchase plus the new Leadership team are the company developments located. Davion Healthcare (NASDAQ:DAVI) stands at USD 1.58 after a 20.61% increase on November 6, 2026, far below the USD 4.04 seen on October 26. Upcoming checkpoints include the purchase closing by year end, the funding of the USD 8 million cash payment and the first reported figures. Leadership has also signaled further deals in the next twelve months.